KAVITA LAMROR, Director, Real World Investigator, Digital Function, Sanofi

Bloomberg School of Public Health, and has an experience spanning >15 years in healthcare. She has global experience across markets in the bio-pharma and devices sector, which enable her to develop Value Evidence strategies across the drug development life cycle for successful market access.

In her current role, she is responsible for driving the RWE efforts for Sanofi’s cardiovascular portfolio. This includes the spectrum of activities from data gap identification & validation with global teams, identifying the right approach & RWD for generating RWE, implementation of the correct analytical approach, and dissemination of results to internal stakeholders & regulatory authorities.

Over the span of her career, Dr. Lamror has been involved in designing and concluding studies from epidemiology, clinical, HEOR, and commercial perspectives. Having worked on patient-level and summary level data, she has enabled evidence generation across multiple therapy areas, within Genmed as well asRare/Orphan drugs & diseases portfolios. As a part of evolving organizations, she has conceptualized and enabled the creation of custom tools and platforms for internal scientific discussions and for payer discussions.

Prior to joining Sanofi, Dr. Lamror has established revenue generating business units at 3 KPOs, where she was responsible for leading the Value Evidence unit (RWE, HEOR modelling & HEOR writing) as a subject matter expert. She pioneered novel analytics in her stint at Novartis.  Her roles have a strong element of prioritizing, and consolidating data to identify, elicit and communicate the incremental value of health interventions, and seamlessly aligning the Dr. Kavita Lamror is a certified clinician with distinction, completed her MPH from Johns Hopkins same to the product value story. Having been a part of multiple executive leadership teams reporting to the board, she has been involved in creating value for organizations through organic growth, as well as through targeted acquisitions.